US20190242915A1 - Method For Quantifying Plasmalogens Using PLA1 Processing - Google Patents
Method For Quantifying Plasmalogens Using PLA1 Processing Download PDFInfo
- Publication number
- US20190242915A1 US20190242915A1 US16/385,328 US201916385328A US2019242915A1 US 20190242915 A1 US20190242915 A1 US 20190242915A1 US 201916385328 A US201916385328 A US 201916385328A US 2019242915 A1 US2019242915 A1 US 2019242915A1
- Authority
- US
- United States
- Prior art keywords
- plasmalogens
- subject
- sample
- choline
- plasma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000012545 processing Methods 0.000 title claims abstract description 67
- 238000000034 method Methods 0.000 title claims abstract description 64
- 101100083853 Homo sapiens POU2F3 gene Proteins 0.000 title 1
- 101100058850 Oryza sativa subsp. japonica CYP78A11 gene Proteins 0.000 title 1
- 101150059175 PLA1 gene Proteins 0.000 title 1
- 102100026466 POU domain, class 2, transcription factor 3 Human genes 0.000 title 1
- 150000002632 lipids Chemical class 0.000 claims abstract description 60
- 201000010099 disease Diseases 0.000 claims abstract description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 36
- 238000000605 extraction Methods 0.000 claims abstract description 22
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 18
- 239000000090 biomarker Substances 0.000 claims abstract description 17
- 230000007062 hydrolysis Effects 0.000 claims abstract description 14
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 97
- 239000003153 chemical reaction reagent Substances 0.000 claims description 72
- 108010013563 Lipoprotein Lipase Proteins 0.000 claims description 63
- 102100022119 Lipoprotein lipase Human genes 0.000 claims description 63
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 54
- 229960001231 choline Drugs 0.000 claims description 52
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 46
- 210000002966 serum Anatomy 0.000 claims description 38
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 36
- 102000003992 Peroxidases Human genes 0.000 claims description 23
- 238000004040 coloring Methods 0.000 claims description 23
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 23
- 108010000659 Choline oxidase Proteins 0.000 claims description 19
- 102000004316 Oxidoreductases Human genes 0.000 claims description 19
- 108090000854 Oxidoreductases Proteins 0.000 claims description 19
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 14
- 150000002327 glycerophospholipids Chemical class 0.000 claims description 13
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N 4-aminoantipyrine Chemical compound CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 claims description 12
- 102000011420 Phospholipase D Human genes 0.000 claims description 11
- 108090000553 Phospholipase D Proteins 0.000 claims description 11
- 206010012289 Dementia Diseases 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000007850 fluorescent dye Substances 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 7
- 208000018737 Parkinson disease Diseases 0.000 claims description 7
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 7
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- 238000012360 testing method Methods 0.000 claims description 7
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 6
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 6
- 210000004556 brain Anatomy 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 206010016256 fatigue Diseases 0.000 claims description 6
- 206010022437 insomnia Diseases 0.000 claims description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 5
- PKYCWFICOKSIHZ-UHFFFAOYSA-N 1-(3,7-dihydroxyphenoxazin-10-yl)ethanone Chemical group OC1=CC=C2N(C(=O)C)C3=CC=C(O)C=C3OC2=C1 PKYCWFICOKSIHZ-UHFFFAOYSA-N 0.000 claims description 4
- HHERNILNMJGICC-UHFFFAOYSA-N 3-(n-ethyl-2-methylanilino)-2-hydroxypropane-1-sulfonic acid Chemical compound OS(=O)(=O)CC(O)CN(CC)C1=CC=CC=C1C HHERNILNMJGICC-UHFFFAOYSA-N 0.000 claims description 4
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 235000011152 sodium sulphate Nutrition 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 238000004128 high performance liquid chromatography Methods 0.000 abstract description 30
- 238000005259 measurement Methods 0.000 abstract description 16
- 238000000105 evaporative light scattering detection Methods 0.000 abstract description 15
- 238000001514 detection method Methods 0.000 abstract description 11
- 210000002381 plasma Anatomy 0.000 description 83
- 239000000523 sample Substances 0.000 description 73
- -1 ether phospholipids Chemical class 0.000 description 53
- 229940031098 ethanolamine Drugs 0.000 description 49
- 239000000243 solution Substances 0.000 description 31
- 150000003904 phospholipids Chemical class 0.000 description 29
- 210000004369 blood Anatomy 0.000 description 21
- 239000008280 blood Substances 0.000 description 21
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 210000003743 erythrocyte Anatomy 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 239000012528 membrane Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 8
- 206010034203 Pectus Carinatum Diseases 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 7
- 239000007853 buffer solution Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 239000013504 Triton X-100 Substances 0.000 description 5
- 229920004890 Triton X-100 Polymers 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 229910001873 dinitrogen Inorganic materials 0.000 description 5
- 235000013372 meat Nutrition 0.000 description 5
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 5
- 238000011088 calibration curve Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000228212 Aspergillus Species 0.000 description 3
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Chemical group CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 3
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 229960000367 inositol Drugs 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Chemical group OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical group OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101710132602 Peroxidase 5 Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Chemical group OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 150000002009 diols Chemical class 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000003617 erythrocyte membrane Anatomy 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical group O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 0 C.C.C.[1*]C=CC(O)C(COP(=O)(O)OC)OC([2*])=O Chemical compound C.C.C.[1*]C=CC(O)C(COP(=O)(O)OC)OC([2*])=O 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- DMBHHRLKUKUOEG-UHFFFAOYSA-N diphenylamine Chemical class C=1C=CC=CC=1NC1=CC=CC=C1 DMBHHRLKUKUOEG-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000008239 natural water Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
- C07F9/103—Extraction or purification by physical or chemical treatment of natural phosphatides; Preparation of compositions containing phosphatides of unknown structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
- C12Q1/28—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving peroxidase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
- G01N2333/918—Carboxylic ester hydrolases (3.1.1)
- G01N2333/92—Triglyceride splitting, e.g. by means of lipase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2864—Sleep disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/323—Arteriosclerosis, Stenosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Definitions
- the present invention relates to a method for quantifying plasmalogens, in other words, a method for measuring the amount of plasmalogens in samples, in particular serum or plasma samples.
- the present invention also relates to a method for examining a subject by using the above method, a biomarker for disease detection, a method for using the biomarker for the disease detection, as well as a kit for the disease detection.
- Glycerophospholipids present in a living body of mammals, such as humans, comprise:
- phospholipids having an ester bond at the sn-1 position of the glycerol backbone (diacyl phospholipids);
- the ether phospholipids comprise:
- plasmalogens Those having a vinyl ether bond (alkenyl acyl phospholipids) are also referred to as plasmalogens.
- a general formula of plasmalogens is described below:
- R 1 and R 2 represent an aliphatic hydrocarbon group.
- R 1 at the sn-1 position is usually an aliphatic hydrocarbon group having 1 to 20 carbon numbers, such as dodecyl group, tetradecyl group, hexadecyl group, octadecyl group, icosanyl group, etc.
- R 2 —CO at the sn-2 position is usually an polyunsaturated alkyl carbonyl group derived from polyunsaturated fatty acids, such as octadecadienoyl group, octadecatrienoyl group, icosatetraenoyl group, icosapentaenoyl group, docosatetraenoyl group, docosapentaenoyl group, docosahexaenoyl group, etc.
- X at the sn-3 position represents a polar group in the above formula.
- X is ethanolamine, choline, serine, inositol or glycerol.
- alkyl acyl phospholipids are present in a very few amounts, while most are alkenyl acyl phospholipids, i.e., plasmalogens. Moreover, in such a mammal, there are a few plasmalogens having serine or inositol, while most of them have ethanolamine or choline. Furthermore, in a living body, the ether phospholipids are mainly contained in a biological membrane (cell membrane), so are other phospholipids.
- the amount of ether phospholipids, such as plasmalogens, for example, as shown in Patent Document 1, is often measured by using red blood cell samples.
- Non-Patent Document 1 the amount of plasmalogens in serum is low in patients with severe disease such as dementia, and Alzheimer's disease. Furthermore, it is suggested that the amount of plasmalogens in serum is lower in patients with metabolic syndrome such as diabetes, arteriosclerosis and other chronic diseases.
- choline phospholipids are the majority amounting to about 68%, followed by about 20% of sphingomyelin, and about 8% of lyso-type choline phospholipids, while ethanolamine phospholipids amount to only about 2 to 3%.
- serum and plasma are not a cell membrane, plasmalogens contained there are a quite few as compared to red blood cells and white blood cells. Accordingly, it was difficult to measure the amount of plasmalogens in serum or plasma.
- HPLC high performance liquid chromatography
- MS/MS tandem mass spectrometry
- the present inventors had studied extensively for the purpose of providing a method for measuring the amount of plasmalogens in samples, in particular serum or plasma, in an easy and inexpensive manner.
- the present inventors found out that, by providing a specific processing with serum or plasma samples and by using HPLC with Evaporative Light Scattering Detector (ELSD) or Mass Spectrometer (MS), a fluorescence plate reader or a plate reader, it enables to measure the amount of plasmalogens in samples with high accuracy in an easy, convenient and inexpensive manner.
- ELSD Evaporative Light Scattering Detector
- MS Mass Spectrometer
- the present invention provides a method for quantifying plasmalogens contained in a sample comprising:
- (A) a step of providing hydrolysis processing of a sample, after which lipid extraction is provided to obtain a lipid sample.
- the sample is serum or plasma.
- the plasmalogens are ethanolamine plasmalogens or choline plasmalogens.
- the hydrolysis processing is performed by phospholipase A1 (PLA1).
- the lipid extraction process is performed by a mixture of hexane and isopropanol (3:2, v/v), or chloroform and methanol (1:2, v/v).
- the above-mentioned method for quantifying plasmalogens contained in a sample may further comprise:
- step (B) a step of subjecting the lipid sample obtained by the step (A) to a measurement.
- the measurement in the step (B) is performed by High Performance Liquid Chromatography (HPLC).
- HPLC High Performance Liquid Chromatography
- the HPLC uses Evaporative Light Scattering Detector or Mass Spectrometer as a detector.
- the above-mentioned method for quantifying plasmalogens contained in a sample may further comprise:
- step (B′) a step of processing/reacting the lipid sample obtained by the step (A) with glycerophospholipid specific phospholipase D (GPL-PLD) to get an ethanolamine or a choline; and
- GPL-PLD glycerophospholipid specific phospholipase D
- step (C′) a step of processing/reacting the ethanolamine or choline obtained by the step (B′) with an amine oxidase or a choline oxidase to produce hydrogen peroxide (H 2 O 2 ), respectively;
- step (D′) a step of reacting the hydrogen peroxide (H 2 O 2 ) produced by the step (C′) with a fluorescent reagent in the presence of a peroxidase to produce a fluorescent compound to measure by a fluorescence plate reader;
- step (D′′) a step of reacting the hydrogen peroxide (H 2 O 2 ) produced by the step (C′) with coloring reagents in the presence of a peroxidase to produce a colored compound to measure by a plate reader.
- the sequence of the addition of GPL-PLD, an amine oxidase or a choline oxidase, a fluorescent reagent or coloring reagents, and a peroxidase is not particularly limited.
- the lipid sample obtained by the step (A) may be added with a combination of GPL-PLD and an amine oxidase (or a choline oxidase), and then added with a combination of a fluorescent reagent (or coloring reagents) and a peroxidase.
- the lipid sample may be added with a combination of GPL-PLD, an amine oxidase (or a choline oxidase), a fluorescent reagent (or coloring reagents), and a peroxidase.
- the lipid sample may be added with an amine oxidase (or a choline oxidase), and then added with GPL-PLD, and finally added with a combination of a fluorescent reagent (or coloring reagents) and a peroxidase. As depicted FIG.
- the lipid sample obtained by the step (A), wherein a sample is hydrolyzed by PLA1, after which lipid extraction is provided goes through reactions of steps (B′), (C′) and (D′ or D′′) sequentially to obtain a fluorescent compound or a colored compound for quantifying plasmalogens.
- the fluorescent reagent is Amplex Red and the fluorescent compound is resorufin.
- the coloring reagents are 4-aminoantipyrine and N-ethyl-N-(2-hydroxy-3-sulfopropyl)-toluidine (TOOS).
- unnecessary water-soluble substances are removed by using alcohol, sodium sulfate, water or any combination thereof.
- the present invention provides a method for examining a subject to determine a risk of developing a disease that is closely associated with a change in the amount of plasmalogens comprising:
- the subject is a human mammal. In another embodiment, the subject is a non-human mammal.
- the method further comprises:
- step (3) a step of determining that a risk of developing a disease is high as a consequence of the step (2), in the case where the amount of plasmalogens contained in a sample derived from the subject measured at the step (1) is either less or greater than that of plasmalogens contained in a sample derived from a healthy subject.
- the disease is dementia, depression, brain fatigue, insomnia, Parkinson's disease, metabolic syndrome, diabetes or arteriosclerosis.
- the present invention provides a biomarker for detecting a disease that is closely associated with a change in the amount of plasmalogens, wherein the biomarker comprises plasmalogens contained in serum or plasma.
- the plasmalogens are ethanolamine plasmalogens or choline plasmalogens.
- the present invention provides a method for using plasmalogens contained in serum or plasma, as a biomarker for detecting a disease that is closely associated with a change in the amount of plasmalogens.
- the plasmalogens are ethanolamine plasmalogens or choline plasmalogens.
- the present invention also provides a test kit for examining a subject of a risk of developing diseases that are closely associated with a change in the amount of plasmalogens comprising:
- a reagent used for hydrolysis processing of a sample a reagent used for hydrolysis processing of a sample
- organic solvents for lipid extraction a reagent used for lipid extraction
- test kit further comprises glycerophospholipid specific phospholipase D.
- the test kit further comprises an amine oxidase or a choline oxidase, a peroxidase, and a fluorescent reagent or coloring reagents.
- the present invention enables to measure the amount of plasmalogens, in particular ethanolamine plasmalogens or choline plasmalogens, contained only in a small quantity in samples especially serum or plasma samples, with high accuracy in an easy, convenient and inexpensive manner.
- the measurement is achieved by using High Performance Liquid Chromatography (HPLC) with Evaporative Light Scattering Detector (ELSD) or Mass Spectrometer (MS), a fluorescence plate reader or a plate reader.
- HPLC High Performance Liquid Chromatography
- ELSD Evaporative Light Scattering Detector
- MS Mass Spectrometer
- quantification methods enables to provide a method for examining a subject to determine or predict a risk of developing disease that is closely associated with a change in the amount of plasmalogens (increase or decrease), such as dementia, depression, brain fatigue, insomnia, Parkinson's disease, metabolic syndrome, diabetes or arteriosclerosis, etc.
- biomarker for detecting the diseases, it enables to examine to determine the risk in an easy and safe manner, further at low cost.
- FIG. 1 is an HPLC chart depicting the total phospholipids after phospholipase A1 (PLA1) processing of plasma.
- FIG. 2 is an HPLC chart depicting the total phospholipids in plasma.
- FIG. 3 is an HPLC chart depicting the total phospholipids after phospholipase A1 processing and hydrochloric acid hydrolysis.
- FIG. 4 is a mass spectrometry chart (total ion chromatogram (TIC)) depicting the total phospholipids in human plasma after phospholipase A1 processing.
- TIC total ion chromatogram
- FIG. 5 is the strategy for enzymatic measurement of ethanolamine plasmalogenes (PE) or choline plasmalogenes (PC).
- PE ethanolamine plasmalogenes
- PC choline plasmalogenes
- FIG. 6 is HPLC chart, where (a) represents the total phospholipids in human plasma, and (b) represents those after the phospholipase A1 processing.
- FIG. 7 is a measurement result of ethanolamine plasmalogens (pl-PE) in human plasma using a fluorescence plate reader with or without phospholipase A1 processing.
- FIG. 8 is a standard curve for (a) ethanolamine plasmalogens and (b) choline plasmalogens (pl-PC).
- FIG. 9 is a measurement result of choline plasmalogens (pl-PC) in human plasma using a fluorescence plate reader.
- FIG. 10 is a measurement result of ethanolamine plasmalogens (pl-PE) in human plasma using a plate reader.
- FIG. 11 is a measurement result of choline plasmalogens (pl-PC) in human plasma using a plate reader.
- FIG. 12 is HPLC chart represents the total phospholipids in human erythrocyte membrane with (lower) and without (upper) the phospholipase A1 processing.
- FIG. 13 is a measurement result of ethanolamine plasmalogens (pl-PE) of human erythrocyte membrane using a fluorescence plate reader with and without the phospholipase A1 processing.
- FIG. 14 is HPLC chart, where represents the total phospholipid of chicken breast muscle (upper), and represents those after the phospholipase A1 processing (lower).
- FIG. 15 is a measurement result of choline plasmalogens (pl-PC) of chicken breast muscle using a fluorescence plate reader.
- a method for quantifying plasmalogens contained in a sample comprises:
- (A) a step of providing hydrolysis processing of a sample, after which lipid extraction processing is provided to obtain a lipid sample.
- the sample may be any sample that contains or is expected to contain plasmalogens.
- the sample is preferably a biological sample derived from a subject.
- the subject may be mammals, i.e., humans and non-human mammals.
- the non-human mammals are, for example, pets, laboratory animals, livestock, and the like. Specifically, it may be dogs, cats, monkeys, cows, horses, sheep, goats, pigs, mice, rats, hamsters, rabbits, etc.
- the subject may also be a biological based material other than mammals that is expected to contain plasmalogens (e.g., shellfish etc.). Further, as long as it is expected to contain plasmalogens, the subject may be a plant tissue, seawater, natural water, fruit juice, beverage, waste liquid, etc.
- the biological sample derived from a subject includes a subject-derived tissue, cell, body fluid (such as blood (whole blood, plasma, serum, blood cell, red blood cell membrane, etc.), cerebrospinal fluid, urine, lymph, saliva, sweat, etc.), extracts thereof and the like.
- the sample may be the one collected from a subject itself, or the one with which a certain processing is provided. According to the present invention, since it is possible to measure plasmalogens contained in samples even in a very small quantity, the sample may be preferably serum or plasma.
- a publicly-known method may be used as a method for obtaining or preparing the sample.
- separating agent or anti-plasmin agent, etc. nor is particularly limited to either use or non-use of EDTA, sodium fluoride, sodium citrate, heparin sodium, monoiodoacetic acid or other anticoagulant or glycolysis inhibitor.
- serum or plasma may be obtained by using an ordinary, publicly known blood sampling method (such as syringe blood collection or vacuum blood collection) from a subject.
- a blood sample may be obtained by being centrifuged (e.g., 1000*g, 5 minutes) to recover the supernatant.
- the hydrolysis processing may be performed by specifically hydrolyzing an acyl bond at the sn-1 position, for example, a processing with phospholipase A1 (PLA1).
- PKA1 phospholipase A1
- Said PLA1 hydrolyzes only an acyl bond, but does not act on ether bonds, at the sn-1 position in the sample. Therefore, the PLA1 processing hydrolyzes diacyl-type phospholipids, but not ether-type phospholipids.
- the PLA1 is not particularly limited to its origin, as long as it can achieve the effect.
- the exemplary PLA1 may be the one derived from Aspergillus orizae .
- Such PLA1 may be purchased from, for example, Sigma-Aldrich Japan or Mitsubishi Kagaku Foods Corporation, etc.
- PLA1 manufactured by Sigma-Aldrich Japan is in liquid form, while those produced by Mitsubishi Kagaku Foods are in powder form containing 25% of PLA1.
- the amount of the PLA1 may be selected as deemed fit, depending on the amount of sample.
- the PLA1 is used preferably 0.01-0.50 ⁇ L, more preferably 0.04-0.20 ⁇ L, per the serum or plasma 10 ⁇ L.
- the hydrolysis reaction by the PLA1 may be performed in suitable solvent, in particular buffer, such solvent may be selected as deemed fit, depending on PLA1 to be used.
- suitable solvent in particular buffer
- it may be used 0.1M citrate buffer solution (pH 4.5).
- it may be performed by dissolving the PLA1 in the above buffer solution, preparing the PLA1 solution at a suitable concentration (e.g., 10-300 mg/L in the case of using powder form of Mitsubishi Chemical Foods), thereby adding the PLA1 solution to 30-50 ⁇ L of serum or plasma.
- the amount of the solvent may be any, as long as it may progress the hydrolysis reaction. Therefore, it is not particularly limited, but it is for example, preferably 1-200 ⁇ L, more preferably 5-200 ⁇ L, per 10 ⁇ L of serum or plasma.
- the hydrolysis reaction conditions can be selected as deemed fit.
- the reaction may be performed at a temperature of preferably 30-70 C, more preferably 45-55° C., further preferably 50° C., to react for preferably 1-5 hr, more preferably 1-2 hr.
- pH is preferably pH3.5-5.5, more preferably pH4-5.
- the hydrolysis reaction may be stopped by cooling.
- the sample is subject to lipid extraction.
- This lipid extraction processing can remove free ethanolamine and choline in the sample. Therefore, it enables to quantify only ethanolamine plasmalogens and choline plasmalogens. It is difficult to quantify plasmalogens without the lipid extraction processing.
- lipid extraction it is preferred to select a method capable of removing free ethanolamine and choline in the sample (e.g., a method using a chloroform-methanol mixed solvent or hexane/isopropanol mixed solvent). Meanwhile, it is ideal to remove in advance lysophospholipids having high water solubility, such as lyso-type ethanolamine phospholipids and lyso-type choline lipids generated by the hydrolysis processing. From this point of view, it is more preferred to select the method using hexane/isopropanol (3:2, v/v) mixed solvent (HIP method) than the Bligh & Dyer method using chloroform/methanol (1:2, v/v).
- a processing may be further provided to remove water-soluble substances such as metal (electrolyte), proteins, or sugars, which are present in lipid samples of the serum or plasma, by using alcohols, sodium sulfate, water or any combination thereof.
- water-soluble substances such as metal (electrolyte), proteins, or sugars, which are present in lipid samples of the serum or plasma, by using alcohols, sodium sulfate, water or any combination thereof.
- hydrolysis processing with the samples preferably the one with PLA1, ether phospholipids (plasmalogens), lysophospholipids and sphingomyelin in the samples are intact, while phospholipids other than those are hydrolyzed.
- the above-mentioned method for quantifying plasmalogens contained in a sample may further comprise:
- step (B) a step of subjecting the lipid sample obtained by the step (A) to a measurement.
- the measurement in the step (B) is performed by High Performance Liquid Chromatography (HPLC).
- HPLC High Performance Liquid Chromatography
- the HPLC measurement may be used with ELSD or LC/MS method with high accuracy in an easy, convenient and inexpensive manner.
- the lipid samples of serum or plasma is obtained by extracting after PLA1 processing.
- HPLC High Performance Liquid Chromatography
- ELSD Evaporative Light Scattering Detector
- MS Mass Spectrometer
- HPLC column includes, but is not limited to, a normal phase column, such as Lichrosphere 100 DIOL (250*3 mm, 5 ⁇ m).
- the eluting solution includes, but is not limited to:
- the action of the PLA1 completely hydrolyzes diacyl-type phospholipids in serum or plasma.
- it may not be limited to the specific column or mobile phase, as long as the HPLC method is capable of complete separation of each phospholipid.
- FIG. 4 shows one of the examples. An area of each peak of the obtained chromatogram represents the content of each lipid component.
- the above-mentioned method for quantifying plasmalogens contained in a sample may further comprise:
- step (B′) a step of processing/reacting the lipid sample obtained by the step (A) with glycerophospholipid specific phospholipase D (GPL-PLD) to get an ethanolamine or choline; and
- GPL-PLD glycerophospholipid specific phospholipase D
- step (C′) a step of processing/reacting the ethanolamine or choline obtained by the step (B′) with an amine oxidase or a choline oxidase to produce hydrogen peroxide (H 2 O 2 ), respectively;
- step (D′) a step of reacting the hydrogen peroxide (H 2 O 2 ) produced by the step (C′) with a fluorescent reagent in the presence of a peroxidase to produce a fluorescent compound to measure by a fluorescence plate reader;
- step (D′′) a step of reacting the hydrogen peroxide (H 2 O 2 ) produced by the step (C′) with coloring reagents in the presence of a peroxidase to produce a colored compound to measure by a plate reader.
- the sequence of the addition of GPL-PLD, an amine oxidase or a choline oxidase, a fluorescent reagent or coloring reagents, and a peroxidase is not particularly limited.
- the lipid sample obtained by the step (A) may be added with a combination of GPL-PLD and an amine oxidase (or a choline oxidase), and then added with a combination of a fluorescent reagent (or coloring reagents) and a peroxidase.
- the lipid sample may be added with a combination of GPL-PLD, an amine oxidase (or a choline oxidase), a fluorescent reagent (or coloring reagents), and a peroxidase.
- the lipid sample may be added with an amine oxidase (or a choline oxidase), and then added with GPL-PLD, and finally added with a combination of a fluorescent reagent (or coloring reagents) and a peroxidase. As depicted FIG.
- the lipid sample obtained by the step (A), wherein a sample is hydrolyzed by PLA1, after which lipid extraction is provided goes through reactions of steps (B′), (C′) and (D′ or D′′) sequentially to obtain a fluorescent compound or a colored compound for quantifying plasmalogens.
- the step (B′) includes processing of the lipid sample obtained in the step (A) with glycerophospholipid specificity phospholipase D (GPL-PLD).
- GPL-PLD glycerophospholipid specificity phospholipase D
- the GPL-PLD hydrolyze a phosphate ester bond at the sn-3 position in the glycerol backborn. Therefore, ethanolamine and choline are generated.
- a peroxidase and a fluorescent reagent to form the fluorescent compound (resorufin), which becomes possible to quantify plasmalogens (ethanol amine plasmalogens or choline plasmalogens) by a fluorescence plate reader.
- the above fluorescent reagent includes, but is not limited to, Amplex Red.
- a plate reader may be used instead of the fluorescence plate reader to quantify plasmalogens (ethanolamine plasmalogens or choline plasmalogens).
- coloring reagents instead of the fluorescent reagent in the presence of a peroxidase, by which generate the coloring compound (violet-blue in the case when 4-aminoantipyrine and N-ethyl-N-(2-hydroxy-3-sulfopropyl)-toluidine (TOOS)) are used.
- the coloring reagents can be selected from the publicly-known ones.
- the examples include phenol or its derivative, a combination of an aniline derivative and 4-aminoantipyrine, leuco dye, diphenylamine derivatives, triaryl imidazole derivatives, etc.
- it is a combination of 4-aminoantipyrine and N-ethyl-N-(2-hydroxy-3-sulfopropyl)-toluidine (TOOS).
- Measuring by a fluorescent plate reader or a plate reader enables to quantify even a very few amount of plasmalogens, in a relatively short time, simultaneously.
- the fluorescent plate reader or plate reader In measuring by the fluorescent plate reader or plate reader, it is selected a range of 450-600 nm. The degree of color development at a given wavelength thus represents the amount of lipid component. In the case of using a fluorescent plate reader, it is possible to quantify with stability and with higher sensitivity than a plate reader.
- the surfactant it may be selected, preferably non-ionic surfactants, more preferably polyoxyethylene alkyl phenyl ether.
- the examples include Triton X-100.
- the amount of the used surfactant for example, is 0.01 to 10 mass %.
- the exemplary buffer includes Tris-HCl buffer, in particular 100 mM Tris-HCl buffer (pH 7.4) and the like.
- the similar effect may be obtained by performing in a manner that the processing with glycerophospholipid specific phospholipase D, the processing with an amine oxidase or a choline oxidase, the processing with a peroxidase are carried out simultaneously instead of stepwise.
- the present invention by using the aforementioned method to quantify plasmalogens, it enables to compare the amount of plasmalogens in samples from a subject with that from a healthy subject to determine for the subject a risk of developing a disease that is closely associated with the change (increase or decrease) in the amount of plasmalogens.
- the examination method is the one for determining a risk of a subject developing a disease that is closely associated with a change in the amount of plasmalogens (increase or decrease) comprising:
- the exemplary disease that is closely associated with the change in the amount of plasmalogens includes dementia, depression, brain fatigue, insomnia, Parkinson's disease, metabolic syndrome, diabetes, arteriosclerosis, and the like.
- it is dementia, depression, brain fatigue, insomnia, Parkinson's disease, a metabolic syndrome, diabetes or arteriosclerosis.
- the exemplary dementia is degenerative dementia. Specifically, dementia associated with Parkinson's disease, frontotemporal dementia, Pick's disease, diffuse Lewy body disease, and Alzheimer's dementia can be exemplified.
- the step (1) describes a step of quantifying plasmalogens contained in a sample derived from a subject according to the quantification method recited above, as the details are described above.
- the step (2) is a step of comparing the amount of plasmalogens in the sample measured at the step (1) with the amount of plasmalogens in a sample derived from a healthy subject.
- this step the followings are compared: (a) the amount of plasmalogens contained in a sample collected from a subject; and (b) the amount of plasmalogens contained in a sample collected from a healthy subject.
- the amount of plasmalogens contained in a sample collected from a healthy subject means in general the amount of plasmalogens contained in a sample (e.g., blood plasma) that belongs to the identical species as the tested subject (e.g., mammals) and that does not suffer from the same disease at least or is preferably healthy.
- the examination method is provided as follows.
- a comparison result between (a) the amount of plasmalogens contained in a sample collected from a subject; and (b) the amount of plasmalogens contained in a sample collected from a healthy subject, it can determine if a risk is high or low of developing a disease that is closely associated with a change in the amount of plasmalogens (increase or decrease) for the subject.
- the examination method may include further a following step: (3) a step of determining a risk of developing a disease is high as a consequence of the step (2), in the case where the amount of plasmalogens contained in samples derived from a subject measured at the step (2) is either less or greater than that of plasmalogens contained in a sample derived from a healthy subject.
- the present invention encompasses a biomarker for detecting a disease that is closely associated with a change in the amount of plasmalogens contained in serum or plasma.
- a biomarker for detecting a disease that is closely associated with a change in the amount of plasmalogens contained in serum or plasma.
- plasmalogens contained in the serum or plasma isolated from a living body is used as the biomarker for disease detection.
- the biomarker according to the present invention is the one for disease detection comprising plasmalogens extracted from serum or plasma.
- the biomarker according to the present invention has a feature that the amount of plasmalogens derived from a subject who develops the disease changes (decreases or increases) as compared to that from a healthy subject.
- the biomarker for disease detection comprises, among plasmalogens, ethanolamine plasmalogens or choline plasmalogens. Therefore, the present invention preferably includes the biomarker for disease detection comprising ethanolamine plasmalogens or choline plasmalogens contained in serum or plasma. According to the present invention, the biomarker can be easily exercised based on the above description.
- the present invention also encompasses a test kit for examining a subject of a risk of developing a disease that is closely associated with a change in the amount of plasmalogens.
- the test kit is provided with a reagent useful for quantifying plasmalogens contained in a sample, and an organic solvent for lipid extraction.
- the exemplary reagent includes a reagent used for hydrolysis processing of samples, specifically, a reagent for hydrolyzing lipids contained in samples, and a reagent useful for producing ethanolamine or choline after the hydrolysis processing. More specifically, it may be phospholipase A1 (PLA1), its solvent (e.g. 0.1M citrate buffer solution), or glycerophospholipids specificity phospholipase D, and the like.
- PHA1 phospholipase A1
- its solvent e.g. 0.1M citrate buffer solution
- glycerophospholipids specificity phospholipase D glycerophospholipids specificity phospholipase D
- the exemplary organic solvent for lipid extraction includes chloroform, chloroform/methanol (preferably 1:2) mixture, hexane, hexane/isopropanol (preferably 3:2) mixture, and the like.
- the kit may be provided with: a blood collection device, such as a blood collection syringe and blood collection tube; further, a reagent for the analysis by the fluorescent plate reader or plate reader, such as GPL-PLD, an amine oxidase, a choline oxidase, a peroxidase, a fluorescent reagent and coloring reagents.
- a blood collection device such as a blood collection syringe and blood collection tube
- a reagent for the analysis by the fluorescent plate reader or plate reader such as GPL-PLD, an amine oxidase, a choline oxidase, a peroxidase, a fluorescent reagent and coloring reagents.
- Venous blood was collected using a syringe.
- EDTA-Na as anticoagulant. This was used as human blood sample.
- the blood sample so obtained was centrifuged at 1000*g for 5 min, and supernatant (i.e. plasma) was recovered.
- Phospholipase A1 (PLA1) solution was prepared by dissolving 25% of PLA1 powder (derived from Aspergillus orizae , manufactured by Mitsubishi Kagaku Foods) with 0.1M citric acid (pH4.5) at a concentration of 200 mg/mL.
- the resulting mixture was centrifuged at 13,000 rpm for 10 minutes.
- the recovered chloroform layer was dried by a nitrogen gas to make it as a plasma sample, which was stored at a temperature of ⁇ 30° C.
- the obtained plasma sample was again dissolved in 200 ⁇ L of hexane/isopropanol (3:2).
- FIG. 1 The result is shown in FIG. 1 .
- HPLC Agilent 1260 System (Agilent Technologies, Tokyo)
- ELSD (1290 Infinity ELSD, Agilent Technologies) Gain 5, N2 gas flow rate 0.99 LSM, evaporator temperature 60° C.
- FIG. 2 depicts HPLC chart representing the total phospholipids in plasma without the PLA1 processing. There is an extremely small amount of ethanolamine plasmalogens and choline plasmalogens contained in human plasma. According to FIG. 2 , it was found that if the total lipids (without processing) were analyzed by the above HPLC method, the separation between diacyl-type phospholipids and ether-type phospholipids resulted in incomplete.
- FIG. 3 depicts the total phospholipids in plasma that was provided phospholipase A1 processing and hydrochloric acid treatment.
- phospholipids are provided hydrochloric acid hydrolysis, alkenyl phospholipids (plasmalogens) are decomposed, while acyl phospholipids and alkyl phospholipids are not decomposed.
- ether phospholipids having choline residue in human plasma contain about 50% of alkyl phospholipids (alkyl PC).
- phospholipids in human serum or plasma are constituted by diacyl choline phospholipids (acyl PC), sphingomyelin (SM-1, SM-2), lyso choline phospholipids (LPC), diacyl ethanolamine phospholipids (acyl PE), diacyl inositol phospholipids (acyl PI), and ether phospholipids, such as alkenyl ethanolamine phospholipids (alkenyl PE), alkenyl, and alkyl choline phospholipids (alkenyl PC, alkyl PC) (See FIG. 2 ).
- acyl PC diacyl choline phospholipids
- SM-1, SM-2 lyso choline phospholipids
- LPC diacyl ethanolamine phospholipids
- acyl PE diacyl inositol phospholipids
- ether phospholipids such as alkenyl ethanolamine phospholipids (alkenyl PE), al
- HPLC Agilent 1260 System (Agilent Technologies, Tokyo) was used as HPLC.
- diacyl-type phospholipids are completely decomposed by the acting of PLA1. Therefore, it is evident that no limit is necessary to a specific column or mobile phase, as long as HPLC is capable of mutual separation of each phospholipid. Furthermore, it is evident that it enables to analyze plasmalogens in serum or plasma by mass spectrometry that is directly linked to HPLC.
- Example 3 Quantifying Ethanolamine Plasmalogens in Plasma with a Fluorescent Reagent
- Venous blood was collected using a heparin-contained blood collection tube (manufactured by Terumo Corporation). The venous blood was used as a human blood sample.
- the blood sample so obtained was centrifuged at 1000*g for 5 min, and supernatant (i.e. plasma) was recovered.
- Phospholipase A1 (derived from Aspergillus orizae , manufactured by Sigma-Aldrich Japan) had been 2-fold diluted by 0.1M citric acid buffer solution (pH4.5). To the plasma was added 10 ⁇ L of the diluted PLA1, and the mixture was well mixed at a temperature of 45° C. for 60 min.
- the combined upper layer (hexane layer) was dried with nitrogen gas to make it as plasma samples, and stored at a temperature of ⁇ 30° C.
- Reagent Solution 1 was obtained by mixing substances shown in TABLE 2, then prepared with 100 mM tris-hydrochloric acid buffer solution (pH 7.4).
- Reagent Solution 2 was obtained by mixing substances show in TABLE 3, then prepared with 100 mM tris-hydrochloric acid buffer solution (pH 7.4).
- the stored plasma samples (lipid samples) and standard phospholipids (phosphatidyl ethanolamine) were added to 200 ⁇ L of 1% Triton X-100, subject to dissolution.
- a calibration curve was created from the measured value of the phosphatidyl ethanolamine (PE).
- both ethanolamine plasmalogens and diacyl type ethanolamine phospholipids are measured.
- Reagent Solution 3 was obtained by mixing substances shown in TABLE 4, then prepared with 100 mM tris-hydrochloric acid buffer solution (pH 7.4).
- the amount of choline plasmalogens in the plasma samples are calculated based on the measured value of the plasma samples.
- Quantifying ethanolamine plasmalogens in plasma is performed by the similar method to EXAMPLE 3, except using Reagent Solution 4 instead of Reagent Solution 2 and a plate reader to measure at wavelength 595 nm instead of a fluorescence plate reader.
- Reagent Solution 4 was obtained by mixing substances shown in TABLE 5, then prepared with 100 mM tris-hydrochloric acid buffer solution (pH 7.4).
- the present invention enables to quantify ethanolamine plasmalogens contained even in a very few amount in serum or plasma simultaneously and in a large scale by using a plate reader.
- Quantifying choline plasmalogens in plasma was performed by the similar method to EXAMPLE 5, except using Reagent Solution 3 instead of Reaction Solution 1. The results are shown in FIG. 11 .
- Washed red blood cell was prepared from a human blood.
- the total lipid obtained was added by 10 ⁇ L of 2-fold diluted solution of phospholipase A1 (PLA1) (manufactured by Sigma-Aldrich Japan), subject to well mixing for reaction at a temperature of 45° C. for 1 hour.
- PHA1 phospholipase A1
- lipid sample 800 ⁇ L of hexane/isopropanol (3:2) was added and mixed to extract lipids, which were dried with nitrogen gas to obtain a lipid sample.
- Quantifying ethanolamine plasmalogens were performed by a method similar to EXAMPLE 3 for the lipid sample obtained.
- diacyl type ethanolamine phospholipids PE are completely decomposed by directly processing extraction liquid from the human red blood cell membrane with phospholipase A1.
- ethanolamine plasmalogens can be measured by processing the lipid extract from a human red blood cell membrane with phospholipase A1, after which are provided processing of lipid extraction and processing by certain enzyme to measure by fluorophotometric analysis.
- the total lipids were extracted from 1 g of chicken breast meat, using 3000 ⁇ L of chloroform-methanol (1:2), subject to dryness with nitrogen gas.
- the lipid samples obtained was quantified for plasmalogens according to the similar methods to EXAMPLE 4.
- choline plasmalogens can be measured by processing the lipid extract from a chicken breast meat with phospholipase A1, after which are provided processing of lipid extraction and processing by certain enzyme to measure by fluorophotometric analysis. Therefore, it is evident that the present invention enables to quantify choline plasmalogens contained in tissues of chicken breast meat, with high accuracy and in an easy and convenient manner, simultaneously and on a massive scale.
- the present invention enables to quantify plasmalogens contained in samples even in a very few amount, with high accuracy in an easy, convenient and inexpensive manner.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Endocrinology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
- The present application is a divisional of U.S. patent application Ser. No. 15/478,487, filed on Apr. 4, 2017, the disclosure of which is incorporated herein by reference.
- The present invention relates to a method for quantifying plasmalogens, in other words, a method for measuring the amount of plasmalogens in samples, in particular serum or plasma samples.
- More specifically, it relates to a method for measuring the amount of plasmalogens in samples with high accuracy in an easy, convenient and inexpensive manner, using High Performance Liquid Chromatography (HPLC) with Evaporative Light Scattering Detector (ELSD) or Mass Spectrometer (MS), a fluorescence plate reader or a plate reader. The present invention also relates to a method for examining a subject by using the above method, a biomarker for disease detection, a method for using the biomarker for the disease detection, as well as a kit for the disease detection.
- Glycerophospholipids present in a living body of mammals, such as humans, comprise:
- (1) phospholipids having an ester bond at the sn-1 position of the glycerol backbone (diacyl phospholipids); and
- (2) phospholipids having an ether bond at the sn-1 position (ether phospholipids).
- The ether phospholipids comprise:
- (1) phospholipids having an ether bond at the sn-1 position (alkyl acyl phospholipids); and
- (2) phospholipids having a vinyl ether bond (alkenyl acyl phospholipids).
- Those having a vinyl ether bond (alkenyl acyl phospholipids) are also referred to as plasmalogens. A general formula of plasmalogens is described below:
- In the above formula, R1 and R2 represent an aliphatic hydrocarbon group.
- R1 at the sn-1 position is usually an aliphatic hydrocarbon group having 1 to 20 carbon numbers, such as dodecyl group, tetradecyl group, hexadecyl group, octadecyl group, icosanyl group, etc.
- R2—CO at the sn-2 position is usually an polyunsaturated alkyl carbonyl group derived from polyunsaturated fatty acids, such as octadecadienoyl group, octadecatrienoyl group, icosatetraenoyl group, icosapentaenoyl group, docosatetraenoyl group, docosapentaenoyl group, docosahexaenoyl group, etc.
- X at the sn-3 position represents a polar group in the above formula. Preferably, X is ethanolamine, choline, serine, inositol or glycerol.
- In ether phospholipids of a mammal such as a human, alkyl acyl phospholipids are present in a very few amounts, while most are alkenyl acyl phospholipids, i.e., plasmalogens. Moreover, in such a mammal, there are a few plasmalogens having serine or inositol, while most of them have ethanolamine or choline. Furthermore, in a living body, the ether phospholipids are mainly contained in a biological membrane (cell membrane), so are other phospholipids.
- The amount of ether phospholipids, such as plasmalogens, for example, as shown in
Patent Document 1, is often measured by using red blood cell samples. - Recently, it was reported to suggest that the amount of plasmalogens in serum is low in patients with severe disease such as dementia, and Alzheimer's disease (for example, see Non-Patent Document 1). Furthermore, it is suggested that the amount of plasmalogens in serum is lower in patients with metabolic syndrome such as diabetes, arteriosclerosis and other chronic diseases.
-
- [Patent Document 1] International Publication No. WO 2012/090625
-
- [Non-Patent Document 1] Goodenowe, D. B. et al., J. Lipid Res., Vol. 48, 2007, pp. 2485-2498
- When calculating phospholipids in human serum or plasma by the amount of phosphorus, choline phospholipids are the majority amounting to about 68%, followed by about 20% of sphingomyelin, and about 8% of lyso-type choline phospholipids, while ethanolamine phospholipids amount to only about 2 to 3%. Further, since the serum and plasma are not a cell membrane, plasmalogens contained there are a quite few as compared to red blood cells and white blood cells. Accordingly, it was difficult to measure the amount of plasmalogens in serum or plasma.
- Recently, a method combining high performance liquid chromatography (HPLC) with tandem mass spectrometry (LC/MS/MS) has been developed for measuring the amount of ether phospholipids in serum or plasma.
- In addition, there has been a method, where radioactive iodine is reacted with vinyl ether bonds, then HPLC fractionates each ether phospholipid to measure the radioactivity by a gamma counter (γ-counter).
- However, since LC/MS/MS and gamma counter are expensive, the measuring method of using either is not suitable for a general clinical testing.
- Under these circumstances, the present inventors had studied extensively for the purpose of providing a method for measuring the amount of plasmalogens in samples, in particular serum or plasma, in an easy and inexpensive manner.
- As a consequence, the present inventors found out that, by providing a specific processing with serum or plasma samples and by using HPLC with Evaporative Light Scattering Detector (ELSD) or Mass Spectrometer (MS), a fluorescence plate reader or a plate reader, it enables to measure the amount of plasmalogens in samples with high accuracy in an easy, convenient and inexpensive manner. The present invention was so completed.
- In one aspect, the present invention provides a method for quantifying plasmalogens contained in a sample comprising:
- (A) a step of providing hydrolysis processing of a sample, after which lipid extraction is provided to obtain a lipid sample.
- In one embodiment, the sample is serum or plasma.
- In one embodiment, the plasmalogens are ethanolamine plasmalogens or choline plasmalogens.
- In one embodiment, the hydrolysis processing is performed by phospholipase A1 (PLA1).
- In one embodiment, the lipid extraction process is performed by a mixture of hexane and isopropanol (3:2, v/v), or chloroform and methanol (1:2, v/v).
- In one aspect, the above-mentioned method for quantifying plasmalogens contained in a sample may further comprise:
- (B) a step of subjecting the lipid sample obtained by the step (A) to a measurement.
- In one embodiment, the measurement in the step (B) is performed by High Performance Liquid Chromatography (HPLC).
- In one embodiment, the HPLC uses Evaporative Light Scattering Detector or Mass Spectrometer as a detector.
- In one aspect, the above-mentioned method for quantifying plasmalogens contained in a sample may further comprise:
- (B′) a step of processing/reacting the lipid sample obtained by the step (A) with glycerophospholipid specific phospholipase D (GPL-PLD) to get an ethanolamine or a choline; and
- (C′) a step of processing/reacting the ethanolamine or choline obtained by the step (B′) with an amine oxidase or a choline oxidase to produce hydrogen peroxide (H2O2), respectively; and
- (D′) a step of reacting the hydrogen peroxide (H2O2) produced by the step (C′) with a fluorescent reagent in the presence of a peroxidase to produce a fluorescent compound to measure by a fluorescence plate reader; or
- (D″) a step of reacting the hydrogen peroxide (H2O2) produced by the step (C′) with coloring reagents in the presence of a peroxidase to produce a colored compound to measure by a plate reader.
- The sequence of the addition of GPL-PLD, an amine oxidase or a choline oxidase, a fluorescent reagent or coloring reagents, and a peroxidase is not particularly limited. In one embodiment, the lipid sample obtained by the step (A) may be added with a combination of GPL-PLD and an amine oxidase (or a choline oxidase), and then added with a combination of a fluorescent reagent (or coloring reagents) and a peroxidase. In one embodiment, the lipid sample may be added with a combination of GPL-PLD, an amine oxidase (or a choline oxidase), a fluorescent reagent (or coloring reagents), and a peroxidase. In one embodiment, the lipid sample may be added with an amine oxidase (or a choline oxidase), and then added with GPL-PLD, and finally added with a combination of a fluorescent reagent (or coloring reagents) and a peroxidase. As depicted
FIG. 5 , the lipid sample obtained by the step (A), wherein a sample is hydrolyzed by PLA1, after which lipid extraction is provided, goes through reactions of steps (B′), (C′) and (D′ or D″) sequentially to obtain a fluorescent compound or a colored compound for quantifying plasmalogens. - In one embodiment, the fluorescent reagent is Amplex Red and the fluorescent compound is resorufin. The coloring reagents are 4-aminoantipyrine and N-ethyl-N-(2-hydroxy-3-sulfopropyl)-toluidine (TOOS).
- In one embodiment, after the step (A) and before the step (B or B′), unnecessary water-soluble substances are removed by using alcohol, sodium sulfate, water or any combination thereof.
- In one aspect, the present invention provides a method for examining a subject to determine a risk of developing a disease that is closely associated with a change in the amount of plasmalogens comprising:
- (1) a step of quantifying plasmalogens according to any one of the methods described above to quantify plasmalogens contained in a sample derived from a subject; and
- (2) a step of comparing the amount of plasmalogens in the sample measured at the step (1) with the amount of plasmalogens in a sample derived from a healthy subject.
- In one embodiment, the subject is a human mammal. In another embodiment, the subject is a non-human mammal.
- In one embodiment, the method further comprises:
- (3) a step of determining that a risk of developing a disease is high as a consequence of the step (2), in the case where the amount of plasmalogens contained in a sample derived from the subject measured at the step (1) is either less or greater than that of plasmalogens contained in a sample derived from a healthy subject.
- In one embodiment, the disease is dementia, depression, brain fatigue, insomnia, Parkinson's disease, metabolic syndrome, diabetes or arteriosclerosis.
- In one aspect, the present invention provides a biomarker for detecting a disease that is closely associated with a change in the amount of plasmalogens, wherein the biomarker comprises plasmalogens contained in serum or plasma.
- In one embodiment, the plasmalogens are ethanolamine plasmalogens or choline plasmalogens.
- In one aspect, the present invention provides a method for using plasmalogens contained in serum or plasma, as a biomarker for detecting a disease that is closely associated with a change in the amount of plasmalogens.
- In one embodiment, the plasmalogens are ethanolamine plasmalogens or choline plasmalogens.
- In one aspect, the present invention also provides a test kit for examining a subject of a risk of developing diseases that are closely associated with a change in the amount of plasmalogens comprising:
- a reagent used for hydrolysis processing of a sample; and organic solvents for lipid extraction.
- In one embodiment, the test kit further comprises glycerophospholipid specific phospholipase D.
- In one embodiment, the test kit further comprises an amine oxidase or a choline oxidase, a peroxidase, and a fluorescent reagent or coloring reagents.
- According to the present invention, it enables to measure the amount of plasmalogens, in particular ethanolamine plasmalogens or choline plasmalogens, contained only in a small quantity in samples especially serum or plasma samples, with high accuracy in an easy, convenient and inexpensive manner. The measurement is achieved by using High Performance Liquid Chromatography (HPLC) with Evaporative Light Scattering Detector (ELSD) or Mass Spectrometer (MS), a fluorescence plate reader or a plate reader.
- Moreover, such quantification methods enables to provide a method for examining a subject to determine or predict a risk of developing disease that is closely associated with a change in the amount of plasmalogens (increase or decrease), such as dementia, depression, brain fatigue, insomnia, Parkinson's disease, metabolic syndrome, diabetes or arteriosclerosis, etc.
- Furthermore, using a biomarker for detecting the diseases, it enables to examine to determine the risk in an easy and safe manner, further at low cost.
-
FIG. 1 is an HPLC chart depicting the total phospholipids after phospholipase A1 (PLA1) processing of plasma. -
FIG. 2 is an HPLC chart depicting the total phospholipids in plasma. -
FIG. 3 is an HPLC chart depicting the total phospholipids after phospholipase A1 processing and hydrochloric acid hydrolysis. -
FIG. 4 is a mass spectrometry chart (total ion chromatogram (TIC)) depicting the total phospholipids in human plasma after phospholipase A1 processing. -
FIG. 5 is the strategy for enzymatic measurement of ethanolamine plasmalogenes (PE) or choline plasmalogenes (PC). -
FIG. 6 is HPLC chart, where (a) represents the total phospholipids in human plasma, and (b) represents those after the phospholipase A1 processing. -
FIG. 7 is a measurement result of ethanolamine plasmalogens (pl-PE) in human plasma using a fluorescence plate reader with or without phospholipase A1 processing. -
FIG. 8 is a standard curve for (a) ethanolamine plasmalogens and (b) choline plasmalogens (pl-PC). -
FIG. 9 is a measurement result of choline plasmalogens (pl-PC) in human plasma using a fluorescence plate reader. -
FIG. 10 is a measurement result of ethanolamine plasmalogens (pl-PE) in human plasma using a plate reader. -
FIG. 11 is a measurement result of choline plasmalogens (pl-PC) in human plasma using a plate reader. -
FIG. 12 is HPLC chart represents the total phospholipids in human erythrocyte membrane with (lower) and without (upper) the phospholipase A1 processing. -
FIG. 13 is a measurement result of ethanolamine plasmalogens (pl-PE) of human erythrocyte membrane using a fluorescence plate reader with and without the phospholipase A1 processing. -
FIG. 14 is HPLC chart, where represents the total phospholipid of chicken breast muscle (upper), and represents those after the phospholipase A1 processing (lower). -
FIG. 15 is a measurement result of choline plasmalogens (pl-PC) of chicken breast muscle using a fluorescence plate reader. - The followings describe embodiments of the present invention. Although the present invention is described mainly by preferred representative examples, the present invention is not limited to such examples.
- According to one embodiment of the present invention, a method for quantifying plasmalogens contained in a sample comprises:
- (A) a step of providing hydrolysis processing of a sample, after which lipid extraction processing is provided to obtain a lipid sample.
- The sample may be any sample that contains or is expected to contain plasmalogens. The sample is preferably a biological sample derived from a subject. The subject may be mammals, i.e., humans and non-human mammals. The non-human mammals are, for example, pets, laboratory animals, livestock, and the like. Specifically, it may be dogs, cats, monkeys, cows, horses, sheep, goats, pigs, mice, rats, hamsters, rabbits, etc. The subject may also be a biological based material other than mammals that is expected to contain plasmalogens (e.g., shellfish etc.). Further, as long as it is expected to contain plasmalogens, the subject may be a plant tissue, seawater, natural water, fruit juice, beverage, waste liquid, etc.
- The biological sample derived from a subject includes a subject-derived tissue, cell, body fluid (such as blood (whole blood, plasma, serum, blood cell, red blood cell membrane, etc.), cerebrospinal fluid, urine, lymph, saliva, sweat, etc.), extracts thereof and the like. The sample may be the one collected from a subject itself, or the one with which a certain processing is provided. According to the present invention, since it is possible to measure plasmalogens contained in samples even in a very small quantity, the sample may be preferably serum or plasma.
- A publicly-known method may be used as a method for obtaining or preparing the sample. For example, in the case of collecting whole blood and serum or plasma, it is not particularly limited to either use or non-use of separating agent or anti-plasmin agent, etc.; nor is particularly limited to either use or non-use of EDTA, sodium fluoride, sodium citrate, heparin sodium, monoiodoacetic acid or other anticoagulant or glycolysis inhibitor. Specifically, serum or plasma may be obtained by using an ordinary, publicly known blood sampling method (such as syringe blood collection or vacuum blood collection) from a subject. For example, a blood sample may be obtained by being centrifuged (e.g., 1000*g, 5 minutes) to recover the supernatant.
- The hydrolysis processing may be performed by specifically hydrolyzing an acyl bond at the sn-1 position, for example, a processing with phospholipase A1 (PLA1).
- Said PLA1 hydrolyzes only an acyl bond, but does not act on ether bonds, at the sn-1 position in the sample. Therefore, the PLA1 processing hydrolyzes diacyl-type phospholipids, but not ether-type phospholipids.
- The PLA1 is not particularly limited to its origin, as long as it can achieve the effect. The exemplary PLA1 may be the one derived from Aspergillus orizae. Such PLA1 may be purchased from, for example, Sigma-Aldrich Japan or Mitsubishi Kagaku Foods Corporation, etc. PLA1 manufactured by Sigma-Aldrich Japan is in liquid form, while those produced by Mitsubishi Kagaku Foods are in powder form containing 25% of PLA1.
- The amount of the PLA1 may be selected as deemed fit, depending on the amount of sample. For example, in the case when processing serum or plasma using liquid PLA1 of Sigma-Aldrich Japan, the PLA1 is used preferably 0.01-0.50 μL, more preferably 0.04-0.20 μL, per the serum or
plasma 10 μL. - Although the hydrolysis reaction by the PLA1 may be performed in suitable solvent, in particular buffer, such solvent may be selected as deemed fit, depending on PLA1 to be used. For example, it may be used 0.1M citrate buffer solution (pH 4.5). In that case, it may be performed by dissolving the PLA1 in the above buffer solution, preparing the PLA1 solution at a suitable concentration (e.g., 10-300 mg/L in the case of using powder form of Mitsubishi Chemical Foods), thereby adding the PLA1 solution to 30-50 μL of serum or plasma.
- The amount of the solvent may be any, as long as it may progress the hydrolysis reaction. Therefore, it is not particularly limited, but it is for example, preferably 1-200 μL, more preferably 5-200 μL, per 10 μL of serum or plasma.
- The hydrolysis reaction conditions can be selected as deemed fit. For Example, the reaction may be performed at a temperature of preferably 30-70 C, more preferably 45-55° C., further preferably 50° C., to react for preferably 1-5 hr, more preferably 1-2 hr. In that case, pH is preferably pH3.5-5.5, more preferably pH4-5.
- The hydrolysis reaction may be stopped by cooling.
- Subsequent to the hydrolysis processing, the sample is subject to lipid extraction. This lipid extraction processing can remove free ethanolamine and choline in the sample. Therefore, it enables to quantify only ethanolamine plasmalogens and choline plasmalogens. It is difficult to quantify plasmalogens without the lipid extraction processing.
- In terms of the lipid extraction, it is preferred to select a method capable of removing free ethanolamine and choline in the sample (e.g., a method using a chloroform-methanol mixed solvent or hexane/isopropanol mixed solvent). Meanwhile, it is ideal to remove in advance lysophospholipids having high water solubility, such as lyso-type ethanolamine phospholipids and lyso-type choline lipids generated by the hydrolysis processing. From this point of view, it is more preferred to select the method using hexane/isopropanol (3:2, v/v) mixed solvent (HIP method) than the Bligh & Dyer method using chloroform/methanol (1:2, v/v).
- After the lipid extraction, a processing may be further provided to remove water-soluble substances such as metal (electrolyte), proteins, or sugars, which are present in lipid samples of the serum or plasma, by using alcohols, sodium sulfate, water or any combination thereof.
- By hydrolysis processing with the samples (such as samples from a subject), preferably the one with PLA1, ether phospholipids (plasmalogens), lysophospholipids and sphingomyelin in the samples are intact, while phospholipids other than those are hydrolyzed.
- In one embodiment, the above-mentioned method for quantifying plasmalogens contained in a sample may further comprise:
- (B) a step of subjecting the lipid sample obtained by the step (A) to a measurement.
- In one embodiment, the measurement in the step (B) is performed by High Performance Liquid Chromatography (HPLC). The HPLC measurement may be used with ELSD or LC/MS method with high accuracy in an easy, convenient and inexpensive manner.
- As described above, the lipid samples of serum or plasma is obtained by extracting after PLA1 processing. By analyzing it with High Performance Liquid Chromatography (HPLC) equipped with a common detector, such as Evaporative Light Scattering Detector (ELSD) or Mass Spectrometer (MS), it enables to detect each plasmalogens present in serum or plasma as completely independent peaks from each other.
- In that case, HPLC column includes, but is not limited to, a normal phase column, such as
Lichrosphere 100 DIOL (250*3 mm, 5 μm). The eluting solution includes, but is not limited to: - Hexane/isopropanol/acetic acid (82:17:1, volume ratio)+0.08% triethylamine (mobile phase A) and
- Isopropanol/water/acetic acid (85:14:1, volume ratio)+0.08% triethylamine (mobile phase B), or
- Hexane/isopropanol/formic acid (82:17:1, volume ratio)+25% aqueous ammonia (mobile phase A) and
- Isopropanol/water/formic acid (85:14:1, volume ratio)+25% aqueous ammonia (mobile phase B), or
- Hexane/isopropanol/1M ammonium formate (82:17:1) (mobile phase A) and
- Isopropanol/water/1M ammonium formate (82:17:1) (mobile phase B), etc.
- It should be noted that, according to the present invention, the action of the PLA1 completely hydrolyzes diacyl-type phospholipids in serum or plasma. Thus, it may not be limited to the specific column or mobile phase, as long as the HPLC method is capable of complete separation of each phospholipid.
FIG. 4 shows one of the examples. An area of each peak of the obtained chromatogram represents the content of each lipid component. - According to one embodiment of the present invention, the above-mentioned method for quantifying plasmalogens contained in a sample may further comprise:
- (B′) a step of processing/reacting the lipid sample obtained by the step (A) with glycerophospholipid specific phospholipase D (GPL-PLD) to get an ethanolamine or choline; and
- (C′) a step of processing/reacting the ethanolamine or choline obtained by the step (B′) with an amine oxidase or a choline oxidase to produce hydrogen peroxide (H2O2), respectively; and
- (D′) a step of reacting the hydrogen peroxide (H2O2) produced by the step (C′) with a fluorescent reagent in the presence of a peroxidase to produce a fluorescent compound to measure by a fluorescence plate reader; or
- (D″) a step of reacting the hydrogen peroxide (H2O2) produced by the step (C′) with coloring reagents in the presence of a peroxidase to produce a colored compound to measure by a plate reader.
- The sequence of the addition of GPL-PLD, an amine oxidase or a choline oxidase, a fluorescent reagent or coloring reagents, and a peroxidase is not particularly limited. In one embodiment, the lipid sample obtained by the step (A) may be added with a combination of GPL-PLD and an amine oxidase (or a choline oxidase), and then added with a combination of a fluorescent reagent (or coloring reagents) and a peroxidase. In one embodiment, the lipid sample may be added with a combination of GPL-PLD, an amine oxidase (or a choline oxidase), a fluorescent reagent (or coloring reagents), and a peroxidase. In one embodiment, the lipid sample may be added with an amine oxidase (or a choline oxidase), and then added with GPL-PLD, and finally added with a combination of a fluorescent reagent (or coloring reagents) and a peroxidase. As depicted
FIG. 5 , the lipid sample obtained by the step (A), wherein a sample is hydrolyzed by PLA1, after which lipid extraction is provided, goes through reactions of steps (B′), (C′) and (D′ or D″) sequentially to obtain a fluorescent compound or a colored compound for quantifying plasmalogens. - The step (B′) includes processing of the lipid sample obtained in the step (A) with glycerophospholipid specificity phospholipase D (GPL-PLD). The GPL-PLD hydrolyze a phosphate ester bond at the sn-3 position in the glycerol backborn. Therefore, ethanolamine and choline are generated.
- By the process where ethanolamine and choline generated by the step (B′) is subject to further processing with an amine oxidase to quantify ethanolamine plasmalogens or with a choline oxidase to quantify choline plasmalogens, hydrogen peroxide (H2O2) is generated.
- In addition, in further process, to the solution containing the hydrogen peroxide is added a peroxidase and a fluorescent reagent to form the fluorescent compound (resorufin), which becomes possible to quantify plasmalogens (ethanol amine plasmalogens or choline plasmalogens) by a fluorescence plate reader. The above fluorescent reagent includes, but is not limited to, Amplex Red.
- Further, a plate reader may be used instead of the fluorescence plate reader to quantify plasmalogens (ethanolamine plasmalogens or choline plasmalogens).
- In that case, to the solution containing the hydrogen peroxide are added coloring reagents instead of the fluorescent reagent in the presence of a peroxidase, by which generate the coloring compound (violet-blue in the case when 4-aminoantipyrine and N-ethyl-N-(2-hydroxy-3-sulfopropyl)-toluidine (TOOS)) are used.
- The coloring reagents can be selected from the publicly-known ones. The examples include phenol or its derivative, a combination of an aniline derivative and 4-aminoantipyrine, leuco dye, diphenylamine derivatives, triaryl imidazole derivatives, etc. Preferably, it is a combination of 4-aminoantipyrine and N-ethyl-N-(2-hydroxy-3-sulfopropyl)-toluidine (TOOS).
- Measuring by a fluorescent plate reader or a plate reader enables to quantify even a very few amount of plasmalogens, in a relatively short time, simultaneously.
- In measuring by the fluorescent plate reader or plate reader, it is selected a range of 450-600 nm. The degree of color development at a given wavelength thus represents the amount of lipid component. In the case of using a fluorescent plate reader, it is possible to quantify with stability and with higher sensitivity than a plate reader.
- By using purified choline plasmalogens and ethanolamine phospholipids, it is possible to quantify their amounts by creating respective calibration curves.
- It is possible to perform in the presence of a suitable surfactant for the processing with glycerophospholipid specific phospholipase D, the processing with an amine oxidase or a choline oxidase, the processing with a peroxidase and a fluorescent reagent, as well as the processing with a peroxidase and coloring reagents.
- As the surfactant, it may be selected, preferably non-ionic surfactants, more preferably polyoxyethylene alkyl phenyl ether. The examples include Triton X-100.
- The amount of the used surfactant, for example, is 0.01 to 10 mass %.
- It may be performed by adjusting a buffer as deemed fit for the foregoing processing: one by the glycerophospholipid specific phospholipase D; and one by an amine oxidase or a choline oxidase, a peroxidase, and a fluorescence reagent or coloring reagents. The exemplary buffer includes Tris-HCl buffer, in particular 100 mM Tris-HCl buffer (pH 7.4) and the like.
- Furthermore, the similar effect may be obtained by performing in a manner that the processing with glycerophospholipid specific phospholipase D, the processing with an amine oxidase or a choline oxidase, the processing with a peroxidase are carried out simultaneously instead of stepwise.
- According to the present invention, by using the aforementioned method to quantify plasmalogens, it enables to compare the amount of plasmalogens in samples from a subject with that from a healthy subject to determine for the subject a risk of developing a disease that is closely associated with the change (increase or decrease) in the amount of plasmalogens.
- According to the present invention, the examination method is the one for determining a risk of a subject developing a disease that is closely associated with a change in the amount of plasmalogens (increase or decrease) comprising:
- (1) a step of quantifying plasmalogens according to any one of above methods, to quantify plasmalogens contained in a samples derived from a subject; and
- (2) a step of comparing the amount of plasmalogens in the sample measured at the step (1) with the amount of plasmalogens in a sample derived from a healthy subject.
- The exemplary disease that is closely associated with the change in the amount of plasmalogens includes dementia, depression, brain fatigue, insomnia, Parkinson's disease, metabolic syndrome, diabetes, arteriosclerosis, and the like. Preferably, it is dementia, depression, brain fatigue, insomnia, Parkinson's disease, a metabolic syndrome, diabetes or arteriosclerosis. The exemplary dementia is degenerative dementia. Specifically, dementia associated with Parkinson's disease, frontotemporal dementia, Pick's disease, diffuse Lewy body disease, and Alzheimer's dementia can be exemplified.
- The step (1) describes a step of quantifying plasmalogens contained in a sample derived from a subject according to the quantification method recited above, as the details are described above.
- The step (2) is a step of comparing the amount of plasmalogens in the sample measured at the step (1) with the amount of plasmalogens in a sample derived from a healthy subject.
- In other words, in this step, the followings are compared: (a) the amount of plasmalogens contained in a sample collected from a subject; and (b) the amount of plasmalogens contained in a sample collected from a healthy subject.
- The term “the amount of plasmalogens contained in a sample collected from a healthy subject” means in general the amount of plasmalogens contained in a sample (e.g., blood plasma) that belongs to the identical species as the tested subject (e.g., mammals) and that does not suffer from the same disease at least or is preferably healthy.
- According to the present invention, the examination method is provided as follows. By using a comparison result between (a) the amount of plasmalogens contained in a sample collected from a subject; and (b) the amount of plasmalogens contained in a sample collected from a healthy subject, it can determine if a risk is high or low of developing a disease that is closely associated with a change in the amount of plasmalogens (increase or decrease) for the subject.
- When (a) is less or greater than (b), it is determined that the subject bears a high risk of developing a disease. In other words, the examination method may include further a following step: (3) a step of determining a risk of developing a disease is high as a consequence of the step (2), in the case where the amount of plasmalogens contained in samples derived from a subject measured at the step (2) is either less or greater than that of plasmalogens contained in a sample derived from a healthy subject.
- The present invention encompasses a biomarker for detecting a disease that is closely associated with a change in the amount of plasmalogens contained in serum or plasma. It should be noted that, instead of plasminogen present in a living body, plasmalogens contained in the serum or plasma isolated from a living body is used as the biomarker for disease detection. Thus, the biomarker according to the present invention is the one for disease detection comprising plasmalogens extracted from serum or plasma. The biomarker according to the present invention has a feature that the amount of plasmalogens derived from a subject who develops the disease changes (decreases or increases) as compared to that from a healthy subject.
- Therefore, by isolating the biomarker from the subject and the healthy subject respectively to measure the amount for comparison, it is possible to diagnose that the subject develops the said disease when the amount of plasmalogens derived from the subject is less or greater than that derived from the healthy subject.
- It is preferred that the biomarker for disease detection comprises, among plasmalogens, ethanolamine plasmalogens or choline plasmalogens. Therefore, the present invention preferably includes the biomarker for disease detection comprising ethanolamine plasmalogens or choline plasmalogens contained in serum or plasma. According to the present invention, the biomarker can be easily exercised based on the above description.
- The present invention also encompasses a test kit for examining a subject of a risk of developing a disease that is closely associated with a change in the amount of plasmalogens. According to the present invention, the test kit is provided with a reagent useful for quantifying plasmalogens contained in a sample, and an organic solvent for lipid extraction.
- The exemplary reagent includes a reagent used for hydrolysis processing of samples, specifically, a reagent for hydrolyzing lipids contained in samples, and a reagent useful for producing ethanolamine or choline after the hydrolysis processing. More specifically, it may be phospholipase A1 (PLA1), its solvent (e.g. 0.1M citrate buffer solution), or glycerophospholipids specificity phospholipase D, and the like.
- The exemplary organic solvent for lipid extraction includes chloroform, chloroform/methanol (preferably 1:2) mixture, hexane, hexane/isopropanol (preferably 3:2) mixture, and the like.
- The kit may be provided with: a blood collection device, such as a blood collection syringe and blood collection tube; further, a reagent for the analysis by the fluorescent plate reader or plate reader, such as GPL-PLD, an amine oxidase, a choline oxidase, a peroxidase, a fluorescent reagent and coloring reagents. According to the present invention, the kit can be easily exercised based on the above description.
- The followings describe the present invention with reference to examples. However, the present invention is not limited to these examples.
- (1) Blood Collection
- Venous blood was collected using a syringe.
- To the blood so collected was added EDTA-Na as anticoagulant. This was used as human blood sample.
- (2) Preparation of Plasma
- The blood sample so obtained was centrifuged at 1000*g for 5 min, and supernatant (i.e. plasma) was recovered.
- (3) Preparation of Plasma Sample
- a. 50 μL of plasma was placed in an EPPENDORF TUBE®.
- b. Phospholipase A1 (PLA1) solution was prepared by dissolving 25% of PLA1 powder (derived from Aspergillus orizae, manufactured by Mitsubishi Kagaku Foods) with 0.1M citric acid (pH4.5) at a concentration of 200 mg/mL.
- c. 150 μL of the phospholipase A1 (PLA1) solution so obtained was added to plasma and well mixed, subject to reaction at a temperature of 50° C. for 1 hour.
- d. To the reaction mixture was added 0.5 mL of chloroform/methanol (1:2), subject to vigorous mixing for 1 min, after which it was placed at a room temperature for 10 min.
- e. The resulting mixture was centrifuged at 13,000 rpm for 10 minutes.
- f. The chloroform layer was recovered and placed onto a separate conical glass tube.
- g. The recovered chloroform layer was dried by a nitrogen gas to make it as a plasma sample, which was stored at a temperature of −30° C.
- (4) HPLC Analysis of the Plasma Sample
- The obtained plasma sample was again dissolved in 200 μL of hexane/isopropanol (3:2).
- Then obtained plasma sample was injected into HPLC to analyze on the conditions below.
- The result is shown in
FIG. 1 . - Conditions for HPLC
- Device used: HPLC Agilent 1260 System (Agilent Technologies, Tokyo)
- Column:
Lichrosphere 100 DIOL (250*3 mm, 5 μm) (Merck, Tokyo) - Flow rate: 0.4 ml/min
- Column temperature: 50° C.
- Detection: ELSD (1290 Infinity ELSD, Agilent Technologies)
Gain 5, N2 gas flow rate 0.99 LSM,evaporator temperature 60° C. - Mobile Phase:
- (A) hexane/isopropanol/acetic acid (82:17:1, v/v, +0.08% triethylamine)
- (B) isopropanol/water/acetic acid (85:14:1, v/v, +0.08% triethylamine) TABLE 1 shows a gradient of mobile phases (A) and (B).
-
TABLE 1 Time Mobile phase Mobile phase (min) (A) (%) (B) (%) 0 96 4 21 63 37 25 15 85 26 15 85 29 96 4 36 96 4 - According to
FIG. 1 , it was found that by directly processing human plasma with PLA1, diacyl phospholipids (acyl PE, acyl PC, acyl PI) were completely decomposed. Thus, after the PLA1 processing, the quantification becomes clear, as each plasmalogens can be detected by independent peaks respectively. - On the other hand,
FIG. 2 depicts HPLC chart representing the total phospholipids in plasma without the PLA1 processing. There is an extremely small amount of ethanolamine plasmalogens and choline plasmalogens contained in human plasma. According toFIG. 2 , it was found that if the total lipids (without processing) were analyzed by the above HPLC method, the separation between diacyl-type phospholipids and ether-type phospholipids resulted in incomplete. - Therefore, according to the present invention, it is evident that it enables to quantify the amount of plasmalogens contained even in a small quantity in serum or plasma, with high accuracy in an easy and convenient manner, further inexpensively.
-
FIG. 3 depicts the total phospholipids in plasma that was provided phospholipase A1 processing and hydrochloric acid treatment. When phospholipids are provided hydrochloric acid hydrolysis, alkenyl phospholipids (plasmalogens) are decomposed, while acyl phospholipids and alkyl phospholipids are not decomposed. According toFIG. 3 , it is indicated that ether phospholipids having choline residue in human plasma contain about 50% of alkyl phospholipids (alkyl PC). - Further, taking into consideration the results shown in
FIG. 1 andFIG. 3 , it was found that phospholipids in human serum or plasma are constituted by diacyl choline phospholipids (acyl PC), sphingomyelin (SM-1, SM-2), lyso choline phospholipids (LPC), diacyl ethanolamine phospholipids (acyl PE), diacyl inositol phospholipids (acyl PI), and ether phospholipids, such as alkenyl ethanolamine phospholipids (alkenyl PE), alkenyl, and alkyl choline phospholipids (alkenyl PC, alkyl PC) (SeeFIG. 2 ). - After the PLA1 processing was provided to human plasma then subjected to the lipid extraction processing as [00125], it was injected to HPLC for the measurement of plasmalogens by linking to a mass spectrometer (MS).
- In this example, like above, HPLC Agilent 1260 System (Agilent Technologies, Tokyo) was used as HPLC.
- In terms of the conditions, the similar ones were used except that Ascentis Express HILLIC 150*2.1 mm (2.7 μm) (Sigma, Tokyo) was used as a column, that mobile phases were (A) acetonitrile and (B) 1.0 mM of ammonium formate (pH3 adjusted by formic acid), and that a flow rate was set by 0.2 mL/min.
- As MS, Agilent 6130 (Agilent Technologies, Tokyo) was used.
- The result is shown in
FIG. 4 . - According to
FIG. 4 , it is found that diacyl-type phospholipids are completely decomposed by the acting of PLA1. Therefore, it is evident that no limit is necessary to a specific column or mobile phase, as long as HPLC is capable of mutual separation of each phospholipid. Furthermore, it is evident that it enables to analyze plasmalogens in serum or plasma by mass spectrometry that is directly linked to HPLC. - (1) Blood Collection
- Venous blood was collected using a heparin-contained blood collection tube (manufactured by Terumo Corporation). The venous blood was used as a human blood sample.
- (2) Preparation of Plasma
- The blood sample so obtained was centrifuged at 1000*g for 5 min, and supernatant (i.e. plasma) was recovered.
- (3) Preparation of Plasma Samples
- a. 20-50 μL of plasma was placed in an EPPENDORF TUBE®.
- b. Phospholipase A1 (PLA1) (derived from Aspergillus orizae, manufactured by Sigma-Aldrich Japan) had been 2-fold diluted by 0.1M citric acid buffer solution (pH4.5). To the plasma was added 10 μL of the diluted PLA1, and the mixture was well mixed at a temperature of 45° C. for 60 min.
- c. Further, 800 μL of hexane/isopropanol (3:2) was added and then placed in an ultrasonic bath for 5 min.
- d. To the resulting mixture, 400 μL of aqueous solution of sodium sulfate (1 g of Na2SO4 was dissolved in 15 mL of water) was added and mixed for 30 sec.
- e. The resulting mixture was centrifuged at 1000*g for 5 min.
- f. 400 μL of the upper layer (hexane layer) was recovered.
- g. To the remaining lower layer (aqueous layer), 400 μL of hexane/isopropanol (7:2) was added and mixed for 10-20 sec.
- h. Those obtained were centrifuged at 1000*g for 5 minutes, and 300 μL of the hexane layer was recovered.
- i. The combined upper layer (hexane layer) was dried with nitrogen gas to make it as plasma samples, and stored at a temperature of −30° C.
- (4) Preparation of Various Reagent Solutions
- (4-1) Preparation of
Reagent Solution 1 -
Reagent Solution 1 was obtained by mixing substances shown in TABLE 2, then prepared with 100 mM tris-hydrochloric acid buffer solution (pH 7.4). -
TABLE 2 Prescription for Reagent Solution 1Glycerophospholipid 50 U/mL specific phospholipase D*1 (2 μL/mL) Amine oxidase*2 2 U/mL Triton X-100 0.2% *1manufactured by Sigma-Aldrich Japan. *2manufactured by Asahi Kasei Pharma Corporation - (4-2) Preparation of
Reagent Solution 2Reagent Solution 2 was obtained by mixing substances show in TABLE 3, then prepared with 100 mM tris-hydrochloric acid buffer solution (pH 7.4). -
TABLE 3 Prescription for Reagent Solution 2Peroxidase 5 U/mL Amplex-Red*3 100 μL Calcium chloride 1.5 mM *3manufactured by Molecular Probes. - (5) Analysis of Plasma Samples by Fluorescence Plate Reader
- a. The stored plasma samples (lipid samples) and standard phospholipids (phosphatidyl ethanolamine) were added to 200 μL of 1% Triton X-100, subject to dissolution.
- b. 10, 20, 30, 40 and 50 μL of the plasma samples were dispensed to wells of a microplate reader.
- c. 50 μL of
Reagent Solution 1 was added and mixed, placed at a temperature of 37° C. for 30 min. - d. Further, 50 μL of
Reagent Solution 2 was added, and placed at a temperature of 37° C. for 30 min. - e. The measurement of the resulting solution was performed at wavelength Ex 540 nm, wavelength Em 590 nm.
- (6) Calculation of the Amount of Ethanolamine Plasmalogens in the Plasma Samples
- A calibration curve was created from the measured value of the phosphatidyl ethanolamine (PE).
- Using the above calibration curve, the amount of ethanolamine plasmalogens in the plasma samples was calculated from the measured value of the plasma samples. The result is shown in
FIG. 8 (a) . - From
FIG. 6 , it is found that diacyl type ethanolamine phospholipids are completely decomposed by directly processing the human plasma with phospholipase A1. - Accordingly, as shown in
FIG. 7 , only ethanolamine plasmalogens are measured by processing with phospholipase A1 to the human plasma, thereafter providing lipid extraction and a certain enzymatic processing, subject to fluorophotometric analysis. Therefore, according to the present invention, it enables to quantify ethanolamine plasmalogens even in a very few amount contained in serum or plasma, with high accuracy and in an easy and convenient manner, simultaneously and on a massive scale. - In the case where the processing with phospholipase A1 is not provided, both ethanolamine plasmalogens and diacyl type ethanolamine phospholipids are measured.
- Quantifying choline plasmalogens in plasma was performed by the similar method to EXAMPLE 3, except using
Reagent Solution 3 instead ofReagent Solution 1.Reagent Solution 3 was obtained by mixing substances shown in TABLE 4, then prepared with 100 mM tris-hydrochloric acid buffer solution (pH 7.4). - Using the calibration curve (
FIG. 8 (b) ) created from the measured value of phosphatidyl choline (PC), the amount of choline plasmalogens in the plasma samples are calculated based on the measured value of the plasma samples. - The results are shown in
FIG. 9 . -
TABLE 4 Prescription for Reagent Solution 3Glycerophospholipid 50 U/mL specific phospho- (2 μL/mL) lipase D*4 Choline oxidase*4 2 U/mL Triton X-100 0.2% *4manufactured by Sigma-Aldrich Japan. - By reference to
FIG. 6 , it is found that human plasma contains by far diacyl type choline phosopholipids (PC) than choline plasmalogens. Therefore, without the present invention, it is not possible to quantify choline plasmalogens contained in a very few amount in serum or plasma. - Quantifying ethanolamine plasmalogens in plasma is performed by the similar method to EXAMPLE 3, except using
Reagent Solution 4 instead ofReagent Solution 2 and a plate reader to measure at wavelength 595 nm instead of a fluorescence plate reader.Reagent Solution 4 was obtained by mixing substances shown in TABLE 5, then prepared with 100 mM tris-hydrochloric acid buffer solution (pH 7.4). - The results are shown in
FIG. 10 . -
TABLE 5 Prescription for Reagent Solution 4Peroxidase 5 U/mL N-ethyl-N-(2-hydroxy-3- 2 mM sulfopropyl)-toluidine (TOOS) 4- aminoantipyrine 1 mM Calcium chloride 1.5 mM Triton X-100 0.1% - As shown in
FIG. 10 , it is evident that the present invention enables to quantify ethanolamine plasmalogens contained even in a very few amount in serum or plasma simultaneously and in a large scale by using a plate reader. - Quantifying choline plasmalogens in plasma was performed by the similar method to EXAMPLE 5, except using
Reagent Solution 3 instead ofReaction Solution 1. The results are shown inFIG. 11 . - with a fluorescent reagent
- (1) Preparation of Human Red Blood Cell Membrane
- a. Washed red blood cell was prepared from a human blood.
- b. 1 mL of the obtained washed red blood cell was hemolyzed and washed using tris-HCl buffer solution to prepare the red blood cell membrane.
- (2) Preparation of Lipid Sample in Human Red Blood Cell Membrane
- a. From the 100 μL of the red blood cell membrane, the total lipids were extracted by using chloroform-methanol (1:2, 3000 μL) and dried.
- b. The the total lipid obtained was added by 10 μL of 2-fold diluted solution of phospholipase A1 (PLA1) (manufactured by Sigma-Aldrich Japan), subject to well mixing for reaction at a temperature of 45° C. for 1 hour.
- c. To the resulting mixture, 800 μL of hexane/isopropanol (3:2) was added and mixed to extract lipids, which were dried with nitrogen gas to obtain a lipid sample.
- (3) Analysis of Red Blood Cell Membrane Sample by Fluorescence Plate Reader
- Quantifying ethanolamine plasmalogens were performed by a method similar to EXAMPLE 3 for the lipid sample obtained.
- The results are shown in
FIG. 13 . - It is found from
FIG. 12 that diacyl type ethanolamine phospholipids (PE) are completely decomposed by directly processing extraction liquid from the human red blood cell membrane with phospholipase A1. - Accordingly, as shown in
FIG. 13 , only ethanolamine plasmalogens (pl-PE) can be measured by processing the lipid extract from a human red blood cell membrane with phospholipase A1, after which are provided processing of lipid extraction and processing by certain enzyme to measure by fluorophotometric analysis. - It is found from
FIG. 12 that without processing with phospholipase A1, it is measured ethanolamine plasmalogens and diacyl type ethanolamine phospholipids altogether. - (1) Preparation of Lipid Sample
- a. The total lipids were extracted from 1 g of chicken breast meat, using 3000 μL of chloroform-methanol (1:2), subject to dryness with nitrogen gas.
- b. To the total lipids obtained, 100 μL of 2-fold diluted phospholipase A1 (PLA1) (manufactured by Sigma-Aldrich Japan) was added, well mixed at a temperature of 45° C. for 1 hour.
- c. To the resulting mixture, 800 μL of hexane/isopropanol (3:2) was added, mixed to extract lipids, and dried with nitrogen gas to obtain a lipid sample.
- (2) Analysis of Chicken Breast Meat Sample by Fluorescent Plate Reader
- The lipid samples obtained was quantified for plasmalogens according to the similar methods to EXAMPLE 4.
- The results are shown in
FIG. 15 . - As shown in
FIG. 15 , only choline plasmalogens can be measured by processing the lipid extract from a chicken breast meat with phospholipase A1, after which are provided processing of lipid extraction and processing by certain enzyme to measure by fluorophotometric analysis. Therefore, it is evident that the present invention enables to quantify choline plasmalogens contained in tissues of chicken breast meat, with high accuracy and in an easy and convenient manner, simultaneously and on a massive scale. - It is found from
FIG. 15 that without processing with phospholipase A1, it is measured choline plasmalogens (ePC) and diacyl choline phospholipids (PC) altogether. In addition, it is found fromFIG. 14 that a chicken breast meat contains diacyl type choline phospholipids (PC) by far more amount as compared to choline plasmalogens. - According to the present invention, it enables to quantify plasmalogens contained in samples even in a very few amount, with high accuracy in an easy, convenient and inexpensive manner.
- Further, by using such a quantifying method, it enables to determine or predict a risk of a subject developing a disease that is closely associated with a change in the amount of plasmalogens, such as dementia, depression, brain fatigue, insomnia, Parkinson's disease, metabolic syndrome, arterial sclerosis, etc. Therefore, it is expected to be widely utilized in the field of medicine.
- Although the invention herein has been described with reference to particular embodiments, it is to be understood that these embodiments are merely illustrative of the principles and applications of the present invention. It is therefore to be understood that numerous modifications may be made to the illustrative embodiments and that other arrangements may be devised without departing from the spirit and scope of the present invention as defined by the appended claims.
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/385,328 US20190242915A1 (en) | 2017-04-04 | 2019-04-16 | Method For Quantifying Plasmalogens Using PLA1 Processing |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/478,487 US10324100B2 (en) | 2017-04-04 | 2017-04-04 | Method for quantifying plasmalogens using PLA1 processing |
US16/385,328 US20190242915A1 (en) | 2017-04-04 | 2019-04-16 | Method For Quantifying Plasmalogens Using PLA1 Processing |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/478,487 Division US10324100B2 (en) | 2017-04-04 | 2017-04-04 | Method for quantifying plasmalogens using PLA1 processing |
Publications (1)
Publication Number | Publication Date |
---|---|
US20190242915A1 true US20190242915A1 (en) | 2019-08-08 |
Family
ID=63669218
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/478,487 Expired - Fee Related US10324100B2 (en) | 2017-04-04 | 2017-04-04 | Method for quantifying plasmalogens using PLA1 processing |
US16/385,328 Abandoned US20190242915A1 (en) | 2017-04-04 | 2019-04-16 | Method For Quantifying Plasmalogens Using PLA1 Processing |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/478,487 Expired - Fee Related US10324100B2 (en) | 2017-04-04 | 2017-04-04 | Method for quantifying plasmalogens using PLA1 processing |
Country Status (1)
Country | Link |
---|---|
US (2) | US10324100B2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111992154A (en) * | 2020-08-20 | 2020-11-27 | 浙江工商大学 | Purification process of plasmalogen |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6025568B2 (en) | 2010-12-28 | 2016-11-16 | 株式会社藤野ブレインリサーチ | Test method to determine dementia by blood sample |
JP6399294B2 (en) | 2014-08-25 | 2018-10-03 | 株式会社 レオロジー機能食品研究所 | Method for quantifying ether phospholipids |
JP6349532B2 (en) | 2014-12-08 | 2018-07-04 | 志郎 馬渡 | Ether phospholipid and process for producing the same |
JP6308393B2 (en) | 2014-12-11 | 2018-04-11 | 株式会社 レオロジー機能食品研究所 | Method for quantification of plasmalogen |
US20180127680A1 (en) | 2015-05-12 | 2018-05-10 | Institute of Rheological Functions of Food | Method for producing ether phospholipids |
-
2017
- 2017-04-04 US US15/478,487 patent/US10324100B2/en not_active Expired - Fee Related
-
2019
- 2019-04-16 US US16/385,328 patent/US20190242915A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US10324100B2 (en) | 2019-06-18 |
US20180284143A1 (en) | 2018-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6399294B2 (en) | Method for quantifying ether phospholipids | |
Hu et al. | Shotgun lipidomics in substantiating lipid peroxidation in redox biology: Methods and applications | |
JP6308393B2 (en) | Method for quantification of plasmalogen | |
CN101896620B (en) | Method and kit for quantification of small, dense LDL cholesterol | |
CN105296597B (en) | Kit for detecting high density lipoprotein cholesterol content | |
CN103080332B (en) | Method for quantifying the amount of cholesterol in high-density lipoprotein 3 | |
CN102947708B (en) | Detection method | |
CN102105792A (en) | Means and methods for assessing liver toxicity | |
US8178311B2 (en) | Multiple quantification of cholesterol in low density lipoprotein | |
Furse et al. | A high-throughput platform for detailed lipidomic analysis of a range of mouse and human tissues | |
Otoki et al. | MS/MS and LC-MS/MS analysis of choline/ethanolamine plasmalogens via promotion of alkali metal adduct formation | |
CN104583419A (en) | Method for removal of triglycerides in lipoproteins other than low-density lipoproteins | |
CN101675337A (en) | Methods for the diagnosis and risk assessment of plasmalogen deficiency mediated diseases of aging | |
CN103080748B (en) | Method for quantifying the amount of cholesterol in high-density lipoprotein 3 | |
EP2495332B1 (en) | METHOD FOR MEASURING CHOLESTEROL IN ApoE-CONTAINING HDL | |
US20190242915A1 (en) | Method For Quantifying Plasmalogens Using PLA1 Processing | |
JP2005287378A (en) | Multiple quantitative determination of cholesterol in low density lipoprotein | |
JP6025568B2 (en) | Test method to determine dementia by blood sample | |
US8795980B2 (en) | Methods for determination of previous ethanol consumption | |
JP4813736B2 (en) | Predictive methods for preeclampsia and other diseases | |
EP1300683A1 (en) | Means of examining nephropathy | |
CN105555963A (en) | Method and reagent for quantifying cholesterol in high density lipoprotein 3 | |
De Biase et al. | Quantitative analysis of ethanolamine plasmalogen species in red blood cells using liquid chromatography tandem mass spectrometry for diagnosing peroxisome biogenesis disorders | |
US8088625B2 (en) | Method for detection of familial combined hyperlipidemia | |
Akmurzina et al. | Using high-performance liquid chromatography/mass spectrometry for the quantification of plasma phospholipids in children with type 1 diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: INSTITUTE OF RHEOLOGICAL FUNCTIONS OF FOOD, JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FUJINO, TAKEHIKO;MAWATARI, SHIRO;REEL/FRAME:048911/0851 Effective date: 20170421 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |